Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lyons

Showing results (1101-1110 of 1,357) with videos related to

Pageof 136
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|May 24, 2016
Association Between Genetic Variation in FOXO3 and Reductions in Inflammation and Disease Activity in Inflammatory PolyarthritisSebastien Viatte, James C Lee, Bo Fu, et al.
Age and Ageing|February 12, 2020
New Horizons in the use of routine data for ageing researchOliver M Todd, Jennifer K Burton, Richard M Dodds, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2004
Substituted piperazines as novel dipeptidyl peptidase IV inhibitorsLinda L Brockunier, Jiafang He, Lawrence F Colwell, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitorsJason M Cox, Bart Harper, Anthony Mastracchio, et al.
Developmental Biology|August 1, 2006
A genetic screen identifies genes essential for development of myelinated axons in zebrafishHans-Martin Pogoda, Nitzan Sternheim, David A Lyons, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitorsCharles G Caldwell, Ping Chen, Jiafang He, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2007
Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitorsJennifer E Kowalchick, Barbara Leiting, KellyAnn D Pryor, et al.
Neuromuscular Disorders : NMD|November 8, 2008
Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex catsPaul T Martin, G Diane Shelton, Peter J Dickinson, et al.
Trials|March 11, 2023
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocolMark E McClure, Seerapani Gopaluni, James Wason, et al.
Brain : a Journal of Neurology|May 13, 2024
Mitigation of TDP-43 toxic phenotype by an RGNEF fragment in amyotrophic lateral sclerosis modelsCristian A Droppelmann, Danae Campos-Melo, Veronica Noches, et al.
Pageof 136

Showing results (1101-1110 of 1,357) with videos related to

Sort By:
Pageof 136
Arthritis & Rheumatology (Hoboken, N.J.)|May 24, 2016
Association Between Genetic Variation in FOXO3 and Reductions in Inflammation and Disease Activity in Inflammatory PolyarthritisSebastien Viatte, James C Lee, Bo Fu, et al.
Age and Ageing|February 12, 2020
New Horizons in the use of routine data for ageing researchOliver M Todd, Jennifer K Burton, Richard M Dodds, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2004
Substituted piperazines as novel dipeptidyl peptidase IV inhibitorsLinda L Brockunier, Jiafang He, Lawrence F Colwell, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitorsJason M Cox, Bart Harper, Anthony Mastracchio, et al.
Developmental Biology|August 1, 2006
A genetic screen identifies genes essential for development of myelinated axons in zebrafishHans-Martin Pogoda, Nitzan Sternheim, David A Lyons, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitorsCharles G Caldwell, Ping Chen, Jiafang He, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2007
Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitorsJennifer E Kowalchick, Barbara Leiting, KellyAnn D Pryor, et al.
Neuromuscular Disorders : NMD|November 8, 2008
Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex catsPaul T Martin, G Diane Shelton, Peter J Dickinson, et al.
Trials|March 11, 2023
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocolMark E McClure, Seerapani Gopaluni, James Wason, et al.
Brain : a Journal of Neurology|May 13, 2024
Mitigation of TDP-43 toxic phenotype by an RGNEF fragment in amyotrophic lateral sclerosis modelsCristian A Droppelmann, Danae Campos-Melo, Veronica Noches, et al.
Pageof 136